Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000628676 | SCV000749582 | uncertain significance | Bloom syndrome | 2022-02-19 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with histidine, which is basic and polar, at codon 1080 of the BLM protein (p.Asp1080His). This variant is present in population databases (rs771767745, gnomAD 0.05%), including at least one homozygous and/or hemizygous individual. This variant has not been reported in the literature in individuals affected with BLM-related conditions. ClinVar contains an entry for this variant (Variation ID: 524808). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002325193 | SCV002610326 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-06-01 | criteria provided, single submitter | clinical testing | The p.D1080H variant (also known as c.3238G>C), located in coding exon 16 of the BLM gene, results from a G to C substitution at nucleotide position 3238. The aspartic acid at codon 1080 is replaced by histidine, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000628676 | SCV001454875 | uncertain significance | Bloom syndrome | 2020-09-16 | no assertion criteria provided | clinical testing |